A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection
Transplant International · 2023
DOI: 10.3389/ti.2023.11834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2023. Verfasst von Lukas K van Vugt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC Transplant Institute, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Kidney Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejection therapy between 2012 and 2022 in our institution were investigated. Graft survival, graft function, lymphocyte depletion, serious infections, malignancies, and patient survival were analyzed and compared with a reference cohort of transplanted patients who did not require alemtuzumab anti-rejection therapy. A total of 225 patients treated with alemtuzumab were identified and compared with a reference cohort of 1,668 patients. Over 60% of grafts was salvaged with alemtuzumab therapy, but graft survival was significantly poorer compared to the reference cohort. The median time of profound T- and B lymphocyte depletion was 272 and 344 days, respectively. Serious infection rate after alemtuzumab therapy was 54.1/100 person-years. The risk of death (hazard ratio 1.75, 95%-CI 1.28–2.39) and infection-related death (hazard ratio 2.36, 95%-CI 1.35–4.11) were higher in the alemtuzumab-treated cohort. In conclusion, alemtuzumab is an effective treatment for severe kidney transplant rejection, but causes long-lasting lymphocyte depletion and is associated with frequent infections and worse patient survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Erasmus MC Transplant Institute, Rotterdam, Netherlands.
- Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
- Department of Internal Medicine, A. Schweitzer Hospital Dordrecht, Dordrecht, Netherlands.
- Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
- Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
- Department of Biostatistics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Zitieren
APA
van Vugt, L. K., van der Zwan, M., Clahsen-van Groningen, M. C., van Agteren, M., Hullegie-Peelen, D. M., De Winter, B. C. M., Reinders, M. E. J., Miranda Afonso, P., & Hesselink, D. A. (2023). A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection. Transplant International. https://doi.org/10.3389/ti.2023.11834
Vancouver
van Vugt LK, van der Zwan M, Clahsen-van Groningen MC, van Agteren M, Hullegie-Peelen DM, De Winter BCM, et al. A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection. Transplant International. 2023. doi:10.3389/ti.2023.11834
BibTeX
@article{vanVugt2023,
author = {van Vugt, Lukas K and van der Zwan, Marieke and Clahsen-van Groningen, Marian C and van Agteren, Madelon and Hullegie-Peelen, Daphne M and De Winter, Brenda C M and Reinders, Marlies E J and Miranda Afonso, Pedro and Hesselink, Dennis A},
title = {A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection},
journal = {Transplant International},
year = {2023},
doi = {10.3389/ti.2023.11834}
}
EUVIMED